Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Solaredge Technologies Inc (SEDG) Price & Performance

Abeona Therapeutics IncTrade
Solaredge Technologies IncTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Solaredge Technologies Inc — how do they compare? Abeona Therapeutics Inc trades at $7.35 (market cap $421.19M), while Solaredge Technologies Inc trades at $32.73 (market cap $2.05B). The key difference: Solaredge Technologies Inc is far larger — about 4.9× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Solaredge Technologies Inc nearer its low. Which is the better fit depends on your goals.

ABEOSEDG
Market Cap
$421.19M$2.05B
Sector
HealthTechnology
52-Week High
$7.45$78.51
52-Week Low
$4.17$25.10
Enterprise Value
$276.10M$1.91B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.

The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.

Solaredge Technologies Inc

SolarEdge Technologies (SEDG) trades at $32.21, up 1.42% today, amid a volatile period following its Q2 2026 earnings beat but weak Q3 guidance. The technical outlook is bearish with key support at $30, while fundamentals show revenue of $1.18B in 2025 but a net loss of -$405M, reflecting margin pressures. Analyst sentiment is mixed with a $35.15 consensus target, but recent downgrades highlight execution risks.

The stock faces headwinds from U.S. residential market challenges and policy dependence, though European growth offers some upside. Risks include high debt and persistent losses, but cost controls and storage expansion could support a turnaround if execution improves.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Solaredge Technologies Inc

SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.

Read more on SEDG